Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Current knowledge on the immune response to SARS-COV-2
- How the response to the novel virus is being studied
- The possibility of future health issues in infected individuals
- Future steps in the research into a COVID-19 infection
Biography
Paul Klenerman trained in medicine at Cambridge and Oxford and specialised in infectious diseases. He did his PhD in viral immunology at Oxford University and a postdoc in Zurich before returning to Oxford to establish a lab looking at immune responses to infection. The work includes studies of hepatitis C and a range of viruses affecting the lungs and liver - looking at how these evade the immune response, and the development of vaccines. He is focused especially on novel T cell responses in the mucosal surfaces which are critical for early host defence. He is an NIHR senior fellow and a Wellcome Trust investigator and holds a chair in the Nuffield Department of Medicine in Oxford.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klenerman, P. (2020, March 20). The immune system response to the SARS-CoV-2 virus [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 7, 2023, from https://hstalks.com/bs/4218/.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Series: Interviews on Covid-19
Transcript
0:00
Interviewer: Professor Klenerman,
thank you for
recording this interview with
us on the very important topic
of how the immune system is fighting this
new coronavirus strain called SARS-CoV-2.
To start this interview, I'll ask you: how
does the immune system fight the usual
coronavirus strains, and
how is this new strain different?
Prof Klenerman: That's a good question
and I'll break it down into little bits.
The immune system has evolved to
fight viruses of any kind, and
coronaviruses and influenza and
other respiratory viruses are definitely
some of the things that have
driven our evolved immune system.
The first thing that happens when a virus
invades a cell is that you get something
called an 'innate response' to the virus,
and that's triggered by the ability
of the body to sense things that are
dangerous, things that shouldn't be there.
So there are components of the virus,
particularly the way it copies itself that
lead to structures that
are alien to normal cells,
and that is very sensitively
reacted to by the body so
a small amount of virus can
trigger a pretty brisk response.
That can happen quite quickly and
it puts all the cells in the location so,
say, the lining of the nose or the upper
airways onto some kind of alert, and
that has two effects, the first is that
the cells themselves can start to generate
mechanisms to fight off the virus, and
they can do that in a number of ways.
Essentially there's a massive
response within the cell,
particularly driven by a set of
small molecules called interferons,
which were discovered
about 60 years ago now.